Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13550955 | 0.83 | EPHX2 (0.33) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL15922467 | 0.77 | PKM (0.52) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL15922465 | 0.77 | PKM (0.52) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL1073665 | 0.77 | PKM (0.52) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL4851089 | 0.76 | GRIN1 (0.62) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Hydrochloric Acid SCHEMBL27730223 | 0.75 | LMNA (0.52) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL12604983 | 0.72 | — | — | |
| SCHEMBL1074133 | 0.70 | — | — | |
| Iodide SCHEMBL23880344 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL17453367 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0870757-A2 | Fluoro-substituted adamantane derivatives | PFIZER INC. (US) | 1998-10-14 | — | — | EP | claimed |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| WO-2011001258-A1 | COMPOSITIONS, METHODS, AND KITS FOR TREATING VIRAL AND BACTERIAL INFECTIONS BY TOCOTRIENOLS, TOCOMONOENOLS, TOCODIENOLS, TOCOPHEROLS, AND THEIR DERIVATES | EVITA LIFE SCIENCE PTE. LTD (SG) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010095041-A2 | COMPOSITIONS, METHODS, AND KITS FOR TREATING INFLUENZA VIRAL INFECTIONS | EXCRX (SINGAPORE) PTE.LTD. (SG) | 2010-08-26 | — | — | WO | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| US-6057364-A | USED FOR TREATING NEUROLOGICAL DISORDERS, SUCH AS MEMORY LOSS AND PARKINSON'S DISEASE, AND BACTERIAL AND VIRAL INFECTIONS | PFIZER INC (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0870757-A2 | Fluoro-substituted adamantane derivatives | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | GRIN1 221/4885GRIN2A 80/4885GRIN2D 320/4885 |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | GRIN1 4826/4885GRIN2A 4854/4885GRIN2D 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.